Two cases of Fabry disease identified in brothers
![]() |
Cho, Ji Eun
(Department of Pediatrics, College of Medicine SoonChunHyang University)
Hong, Yong Hee (Department of Pediatrics, College of Medicine SoonChunHyang University) Lee, Yang Gyun (Physical Medicine & Rehabilitation, College of Medicine SoonChunHyang University) Yoo, Han Wook (Department of Pediatrics, Asan Medical Center College of Medicine, University of Ulsan) Lee, Dong Hwan (Department of Pediatrics, College of Medicine SoonChunHyang University) |
1 | Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54 DOI ScienceOn |
2 | Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet A, Sly W, Valle D, Childs R, Kinzler K, editors. Metabloic and molecular bases of inherited disease. 8th ed. New York: Mcgraw Hill, 2001;3733-74 |
3 | Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001;429:23-37 DOI PUBMED ScienceOn |
4 | Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr 2009;168:1355-63 DOI ScienceOn |
5 | Beer M, Weidemann F, Breuning F, Knoll A, Koeppe S, Machann W, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006;97:1515-8 DOI ScienceOn |
6 | Masson C, Cisse I, Simon V, Insalaco P, Audran M. Fabry disease. Joint Bone Spine 2004;71:381-3 DOI ScienceOn |
7 | Fabry H. Angiokeratoma corporis diffusum—Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatrica 2002;91(439 Suppl):3S-5S DOI |
8 | Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl Med 1967;276:1163-7 DOI ScienceOn |
9 | Ries M, Kim HJ, Zalewski CK, Mastroianni MA, Moore DF, Brady RO, et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007;130:143-50 DOI ScienceOn |
10 | Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci USA 1988;85:3903-7 DOI |
11 | Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 2008;64:550-5 DOI ScienceOn |
12 | McGovern MM, Desnick RJ. Lipidoses. In: Robert MK, Richard EB, Hal BJ, Bonita FS, editors. Nelson textbook of pediartics. 18th ed. Philadelphia: WB Saunders Co, 2004:593-600 |
13 | Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alphagalactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16 DOI PUBMED ScienceOn |
14 | Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS editors. Metabolic and molecular bases of inherited disease. 8th ed. New York: Mcgraw Hill, 2001:3733-74 |
15 | Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):20S-6S DOI ScienceOn |
16 | Schiffmann R. Fabry disease. Pharmacol Ther 2009;122:65-77 DOI PUBMED ScienceOn |
17 | Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152:563-70 DOI ScienceOn |
18 | Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-92 DOI ScienceOn |
![]() |